Pharmacokinetic studies of naproxen amides of some amino acid esters with promising colorectal cancer chemopreventive activity

被引:4
作者
Aboul-Fadl, Tarek [1 ,4 ]
Al-Hamad, Soliman S. [2 ]
Fouad, Ehab A. [3 ,5 ]
机构
[1] Assiut Univ, Fac Pharm, Dept Med Chem, Assiut 71526, Egypt
[2] King Saud Univ, Coll Pharm, Dept Pharm Chem, POB 2457, Riyadh 11451, Saudi Arabia
[3] Assiut Univ, Fac Pharm, Dept Pharmaceut, Assiut 71526, Egypt
[4] King Saud Univ, Coll Pharm, POB 2457, Riyadh 11451, Saudi Arabia
[5] Almaarefa Colleges Sci & Technol, Dept Pharmaceut, POB 71666, Riyadh 11597, Saudi Arabia
关键词
Naproxen amides; Prodrugs; Bioavailability; Degradation kinetics; Psudo first-order kinetics; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; DERIVATIVES; PRODRUGS; BIOLOGY; NSAIDS;
D O I
10.1016/j.bioorg.2017.12.006
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Naproxen (nap) is belonging to Non-steriodal anti-inflammatory drugs (NSAIDs) group of drugs that characterized by their free carboxylic group. The therapeutic activity of nap is usually accompanied by GI untoward side effects. Recently synthesized naproxen amides of some amino acid esters prodrugs to mask the free carboxylic group were reported. Those prodrugs showed a promising colorectal cancer chemopreventive activity. The current study aims to investigate the fate and hydrolysis of the prodrugs kinetically in different pH conditions, simulated gastric and intestinal fluids with pHs of 1.2, 5.5 and 7.4 in vitro at 37 degrees C. The effect of enzymes on the hydrolysis of prodrugs was also studied through incubation of these prodrugs at 37 degrees C in human plasma and rat liver homogenates. The pharmacokinetic parameters of selected prodrugs and the liberated nap were studied after oral and intraperitoneal administration in male wistar rats. The results showed the hydrolysis of naproxen amides of amino acid esters to nap through two steps first by degradation of the ester moiety to form the amide of nap with amino acid and the second was through the degradation of the amide link to liberate nap. The two reactions were followed and studied kinetically where K1 and K2 (rate constants of degradation) is reported. The hydrolysis of prodrugs was faster in liver homogenates than in plasma. The relative bioavailability of the liberated nap in vivo was higher in case of prodrug containing ethyl glycinate moiety than that occupied L-valine ethyl ester moiety. Each of nap. prodrugs containing ethyl glycinate and L-valine ethyl ester moieties appears promising in liberating nap, decreasing direct GI side effect and consequently their colorectal cancer chemopreventive activity. (C) 2017 Elsevier Inc. All rights reserved.
引用
收藏
页码:370 / 379
页数:10
相关论文
共 20 条
  • [11] Kyung-Soo C., 2004, BIOCHEM PHARMACOL, V68, P1089
  • [12] Cyclooxygenase-2 and gastrointestinal cancer
    Mann, JR
    DuBois, RN
    [J]. CANCER JOURNAL, 2004, 10 (03) : 145 - 152
  • [13] ROBERT TS, 1989, AM J MED, V86, P449
  • [14] Cyclooxygenase isozymes: The biology of prostaglandin synthesis and inhibition
    Simmons, DL
    Botting, RM
    Hla, T
    [J]. PHARMACOLOGICAL REVIEWS, 2004, 56 (03) : 387 - 437
  • [15] A mechanism for cox-2 inhibitor anti-inflammatory activity in chemoprevention of epithelial cancers
    Smith, ER
    Daly, MB
    Xu, XX
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2004, 13 (01) : 144 - 145
  • [16] Synthesis of functionalised polyethylene glycol derivatives of naproxen for biomedical applications
    Stefanko, Maciej J.
    Gun'ko, Yurii K.
    Rai, Dilip K.
    Evans, Paul
    [J]. TETRAHEDRON, 2008, 64 (44) : 10132 - 10139
  • [17] Nonsteroidal anti-inflammatory drugs as anticancer agents: Mechanistic, pharmacologic, and clinical issues
    Thun, MJ
    Henley, SJ
    Patrono, C
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2002, 94 (04): : 252 - 266
  • [18] A TOXICOLOGIC STUDY OF DIMETHYL SULFOXIDE
    WILLSON, JE
    BROWN, DE
    TIMMENS, EK
    [J]. TOXICOLOGY AND APPLIED PHARMACOLOGY, 1965, 7 (01) : 104 - &
  • [19] Chemoprevention of lung cancer - from biology to clinical reality
    Winterhalder, RC
    Hirsch, FR
    Kotantoulas, GK
    Franklin, WA
    Bunn, PA
    [J]. ANNALS OF ONCOLOGY, 2004, 15 (02) : 185 - 196
  • [20] YAMAOKA K, 1983, J PHARMACOBIO-DYNAM, V6, P595